红桃视频

, an Austin-based digital health company, secured $175 million in an oversubscribed Series D round to expand its consumer testing and virtual care offerings. With the new investment, CEO confirmed the company鈥檚 valuation at $1.3 billion.

Subscribe to the 红桃视频 Daily

鈥淭his represented a mass majority of the funding we have received and the result of our company鈥檚 shift into hypergrowth,鈥� Cheek told 红桃视频 News. 鈥淭his massive growth is an underlying shift that is more broad than just COVID-19. We see an opportunity to partner with telehealth providers and develop broader access to services that could turn into other offerings.鈥�

Everlywell provides more than 30 at-home collection tests for everything from prevention and management, fertility, nutrition and STIs. Three-fourths of the company鈥檚 testing growth was 100 percent year over year. It also reached its 1 million-person milestone this year, quadrupled sales and grew from a workforce of 90 to 200, she added.

The company is one of approximately 158 U.S.-based companies described as working in the that raised some $3.5 billion in venture-based funding in the past five years, according to a search of the 红桃视频 database. Among that list, 43 received funding in 2020.

New investors participating in the round include funds and accounts managed by , , , , , and , as well as existing investors , and .

The new investment brings the total capital raised by the company to more than $250 million since it was founded in 2016, including a round led by Highland Capital in February, Cheek said. We reported on Everlywell鈥檚 $50 million Series B in 2019, and more recently in May when the company was granted emergency use authorization for its COVID-19 Test Home Collection Kit.

Photo of Everlywell CEO Julia Cheek courtesy of the company
Blogroll illustration: